Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-966-0 | CAS number: 101-68-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Sensitisation data (human)
Administrative data
- Endpoint:
- sensitisation data (humans)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Does not include experimental toxicological data
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Diisocyanate asthma: clinical aspects and immunopathogenesis
- Author:
- Redlich CA & Karol MH
- Year:
- 2 002
- Bibliographic source:
- Int.Immunopharmacol. 2 (2/3): 213-24
Materials and methods
- Study type:
- other: Review paper
Test guideline
- Qualifier:
- no guideline followed
Test material
- Reference substance name:
- m-tolylidene diisocyanate
- EC Number:
- 247-722-4
- EC Name:
- m-tolylidene diisocyanate
- Cas Number:
- 26471-62-5
- IUPAC Name:
- 2,4-diisocyanato-1-methylbenzene, 2,6-diisocyanato-1-methylbenzene
- Details on test material:
- Commercial Diisocyanates.
Constituent 1
Method
- Subjects:
- Not Applicable
- Clinical history:
- Not Applicable
- Controls:
- Not Applicable
- Details on study design:
- This review considers recent concepts in exposure, clinical aspects and pathogenesis of the disease. It concludes that the pathogenesis of diisocyanate asthma remains unclear, with evidence supporting both immunological and nonimmunological mechanisms. Recent findings of chemical interactions with biological nucleophiles are described.
Results and discussion
- Results of examinations:
- Diisocyanates, highly reactive chemicals used in the production of polyurethanes, are currently the most frequently reported cause of chemically induced occupational asthma and their use continues to rise. The prevalence of diisocyanate asthma among exposed workers is estimated to range from 5% to 15%. The exposure relationship of TDI and occupational asthma was reviewed extensively. It has declined extensively since the mid-1970s from 5 to 6% to less than 1% due to engineering and work practice control in the workplace. (Ott 2003) Other investigators found low prevalence of occupational asthma 3/243 (1.23%) and antibody-dependent sensitization 2/243 (.82%) to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates, thus concluding that strict control and monitoring of ambient MDI exposure was associated with a low prevalence of specific sensitization to MDI and a lower than expected prevalence of OA. Routes of exposure include the respiratory tract and skin. Workplace exposures are difficult to quantify and control, and there is no simple diagnostic test for the disease.
Other investigators found low prevalence of occupational asthma 3/243 (1.23%) and antibody-dependent sensitization 2/243 (.82%) to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates, thus concluding that strict control and monitoring of ambient MDI exposure was associated with a low prevalence of specific sensitization to MDI and a lower than expected prevalence of OA. (Bernstein et al 1992)
Any other information on results incl. tables
Clinical presentation: Although, the clinical presentation of diisocyanate asthma is variable, often complicating its recognition and diagnosis, industry experience has been that regular respiratory surveillance and early removal of workers who develop toluene diisocyanate (TDI)-associated occupational asthma can effectively protect these workers from accelerated pulmonary function decline (Conner III 43838) This study also suggested that diisocyanates are such well known occupational asthmagens that other exposures tend to be ignored when considering respiratory health problems in a workplace. For example in one industrial hygiene air monitoring program demonstrated excellent control of the polyisocyanate hazard, but poor control of a mould-release solution, which was considered the cause of health problems. Control of that exposure allowed previously restricted workers to return to their former work making polyurethane parts.
Symptoms of diisocyanate asthma typically do not manifest until after an unpredictable latency period of several months to years after initial exposure. Lower respiratory track symptoms begin insidiously and include cough, chest tightness, shortness of breath, or wheezing, which are temporally related to workplace exposure. Upper respiratory symptoms have not been reported. A study of specific nasal responses in subjects undergoing challenges by inhaling occupational agents causing asthma through the nose and mouth, failed to demonstrate significant response in terms of symptoms and increase in nasal resistance or significant changes in inflammatory cells and mediators in subjects exposed to diisocyanates, unlike high molecular weight agents (Desrosiers M et al Allergy. 1998 Sep;53(9):840-8).
Acute high diisocyanate exposures can also cause reactive airways dysfunction syndrome (RADS), an asthma-like illness that develops after a single exposure to a high concentration of an irritating substance. At least two reports have described cases of RADS that have transformed to immunological asthma. (Perfetti et al American journal of industrial medicine 44:325-328 (2003) Leroyer et al Thorax 1998).
Applicant's summary and conclusion
- Conclusions:
- Diisocyanate-associated asthma is the most frequent health effect resulting from exposure which is inadequately controlled. In the early years of the industry, annual incidence ranged from 1% to as high as 5-6% with corresponding high prevalence rates. Since the implementation of hazard control through engineering and work practices in the mid-1970s, , this incidence has declined to less than 1%The pathogenesis of diisocyanate asthma remains unclear, with evidence supporting both immunological and non-immunological mechanisms. The diagnosis of diisocyanate asthma is often problematic due to the variability of symptoms, the lack of simple diagnostic or screening tests, uncertainty regarding the underlying mechanisms, and the multiple other potential occupational and environmental causes of asthma. The clinical presentation and the approach to diagnosing diisocyanate asthma are similar to that of other causes of occupational asthma. Early diagnosis leads to better prognosis; therefore a well designed medical surveillance program is vitally important. Accurate diagnosis is equally important to avoid undue restrictions from the workplace.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.